Prime Medicine, Inc. (PRME) options chain – Yahoo Finance
This article provides the options chain for Prime Medicine, Inc. (PRME), displaying call and put options with an expiration date of January 19, 2029. It includes various strike prices, last trade dates, last prices, bid/ask spreads, volume, open interest, and implied volatility for each option contract. The current stock price for PRME is also noted.
Prime Medicine (NASDAQ:PRME) Cut to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Prime Medicine (NASDAQ:PRME) from "Hold" to "Sell," despite a broader analyst consensus of "Moderate Buy" with a $7.47 target price. The company's shares opened at $2.98, near their 12-month low, and reported a quarterly loss of $0.24 per share on revenue of $1.15 million, significantly missing analyst estimates. Institutional investors, including Alphabet and BlackRock, hold a substantial 70.37% stake in the company.
Prime Medicine's (PRME) Buy Rating Reaffirmed at Chardan Capital
Chardan Capital has reaffirmed its "buy" rating on Prime Medicine (NASDAQ:PRME), setting a price target of $7.00, suggesting a potential upside of 134.11%. Other analysts have also issued positive ratings, contributing to a consensus "Moderate Buy" rating with an average target price of $7.47. The company's stock recently traded down, and it reported a quarterly EPS of ($0.24) and revenue of $1.15 million, below analyst estimates.
Bank of America Corp DE Makes New $3.62 Million Investment in Prime Medicine, Inc. $PRME
Bank of America Corp DE has invested $3.62 million in Prime Medicine, Inc. (NASDAQ:PRME), acquiring 981,335 shares. This new position gives Bank of America a 0.54% stake in the biotechnology company. Institutional investors collectively own 70.37% of Prime Medicine, which focuses on developing genetic medicines using its proprietary Prime Editing platform.
Prime Medicine receives FDA clearance for PM647 in alpha-1 antitrypsin deficiency
Prime Medicine (Nasdaq: PRME) has received FDA clearance for PM647, a one-time in vivo prime editing therapy for alpha-1 antitrypsin deficiency (AATD). This therapy aims to correct the genetic defect, addressing both lung and liver manifestations with a single treatment. Initial clinical data are anticipated in 2027, placing PM647 in a competitive field of genetic medicines for AATD.
Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency
Prime Medicine has announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for PM647. This drug is intended for the treatment of Alpha-1 Antitrypsin Deficiency. The clearance allows Prime Medicine to proceed with clinical trials for PM647.
PRME Stock Dips As Prime Medicine Faces Steep Losses
Prime Medicine Inc. (PRME) stock has fallen by 3.91% due to cautious sentiment regarding its gene-editing therapy pipeline. The company is facing significant losses and a severe cash burn, with analyst sentiment remaining neutral. Technically, PRME is in a short-term downtrend, trading below key resistance levels, indicating persistent selling pressure despite its balance sheet cushion.
Prime Medicine Gets FDA Green Light for Gene Editing Study
Prime Medicine (NASDAQ: PRME) has received FDA clearance for its Investigational New Drug (IND) application for PM647, a gene-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). The company plans to initiate a global Phase 1/2 clinical trial to assess the safety and efficacy of PM647, which aims to correct the E342K (Pi*Z) mutation in the SERPINA1 gene. PM647 is designed to restore functional M-AAT protein levels to address both liver and lung complications of AATD.
FDA Clears Prime Medicine to Start Gene Editing Trial After Beam Dispute
The FDA has given Prime Medicine clearance to begin a gene editing trial. This decision follows a dispute with Beam Therapeutics. The article was published on September 25, 2026.
Prime Medicine stock surges on FDA IND clearance
Prime Medicine Inc. shares surged over 12% in after-hours trading following the FDA's clearance of its Investigational New Drug (IND) application for PM647. This gene editing therapy targets Alpha-1 Antitrypsin Deficiency (AATD) and is set to proceed to a Phase 1/2 clinical trial in the United States, with initial clinical data expected in 2027. PM647 is designed to correct the E342K mutation in the SERPINA1 gene, aiming to restore functional protein production and treat both liver and lung manifestations of AATD.
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
Prime Medicine, Inc. announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for PM647, an in vivo Prime Editor for Alpha-1 Antitrypsin Deficiency (AATD). This clearance allows PM647 to proceed to clinical study in the U.S., targeting the genetic root cause of AATD with potential initial clinical data expected in 2027. The company highlights this as a significant milestone, showcasing the modularity and productivity of its Prime Editing platform.
FDA clears testing of a genetic treatment aimed at a variant carried by about 100,000 people in the U.S.
Prime Medicine has received FDA clearance for its investigational new drug application for PM647, a genetic treatment targeting Alpha-1 Antitrypsin Deficiency (AATD) which affects approximately 100,000 people in the U.S. The clearance allows for a Phase 1/2 clinical study in adults with lung-only AATD, with a later expansion to include patients with liver disease. Initial clinical data is expected in 2027.
Can Prime Medicine (NASDAQ:PRME) Afford To Invest In Growth?
This article analyzes Prime Medicine's financial health to determine its capacity for growth investment, focusing on its cash reserves and burn rate. It highlights that while the company has a substantial cash balance, its high cash burn rate suggests it has limited time before needing to raise additional funds. Investors are advised to monitor the company's progress and potential future dilution.
Prime Medicine, Inc. (NASDAQ:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts
Nine analysts currently cover Prime Medicine, Inc. (NASDAQ:PRME), with a consensus "Moderate Buy" rating and an average 12-month price target of $7.47, significantly above its current $3.19 share price. While the company met EPS expectations with a ($0.24) loss per share, its Q2 revenue of $1.15 million missed estimates of $4.40 million, highlighting ongoing financial challenges. Institutional investors hold a substantial 70.37% of PRME stock, with many increasing or initiating positions in the second quarter.
Prime Medicine at Morgan Stanley conference: editing push faces delivery test
Prime Medicine highlighted its prime editing platform at the Morgan Stanley 24th Annual Global Healthcare Conference, emphasizing its potential for broader and safer gene correction compared to older gene-editing tools, despite delivery remaining a significant challenge, especially for organs like the brain and lungs. The company provided updates on its clinical pipeline, including progress in Wilson's disease, Alpha-1 antitrypsin deficiency, and chronic granulomatous disease, with key proof-of-concept data expected in 2027. Prime Medicine also discussed regulatory interactions and its competitive positioning, aiming to differentiate through its ability to achieve permanent, wild-type protein correction.
Prime Medicine (NASDAQ:PRME) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded Prime Medicine (NASDAQ:PRME) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average target price of $7.47. The biotechnology company's shares opened at $3.13, and it reported a quarterly loss of $0.24 per share, meeting estimates, but revenue of $1.15 million fell short of expectations. Institutional investors hold approximately 70.37% of the stock.
Prime Medicine (NASDAQ:PRME) Stock Price Down 4.3% - Here's What Happened
Prime Medicine (NASDAQ:PRME) shares dropped 4.3% to $3.21 on Friday, with trading volume significantly lower than average. Despite the dip and a revenue miss in its latest earnings report, analysts maintain a "Moderate Buy" rating with a target price well above the current stock price. Institutional investors, including Alphabet and BlackRock, have substantial holdings in the company.
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME
BlackRock Inc. has acquired a significant stake of 9,602,041 shares in Prime Medicine, Inc. (NASDAQ:PRME) during the second quarter, valued at approximately $35.4 million, representing 5.32% of the company. This acquisition contributes to institutional investors collectively owning 70.37% of Prime Medicine. The company currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $7.47, despite reporting a quarterly loss in line with estimates but lower-than-expected revenue.
Prime Medicine (NASDAQ:PRME) Upgraded to Strong-Buy at Chardan Capital
Chardan Capital has upgraded Prime Medicine (NASDAQ:PRME) to a "strong-buy" rating. Despite the upgrade, the biotechnology company reported a quarterly loss matching estimates but revenue significantly below expectations. Institutional investors and hedge funds, including Alphabet Inc., hold a substantial portion of the company's stock.
ADAR1 Capital Management LLC Makes New Investment in Prime Medicine, Inc. $PRME
ADAR1 Capital Management LLC has made a new investment in Prime Medicine, Inc. (NASDAQ:PRME), purchasing over 1.99 million shares valued at approximately $7.37 million. This makes ADAR1 Capital Management LLC a significant institutional holder with 1.10% of Prime Medicine's stock. Other institutional investors like Alphabet Inc., BlackRock Inc., State Street Corp, and Vanguard Group Inc. have also recently acquired or increased their stakes in the biotechnology company.
Prime Medicine (NASDAQ:PRME) Shares Up 6.3% - Here's What Happened
Prime Medicine (NASDAQ:PRME) saw its shares increase by 6.3% on Tuesday, closing at $3.4550, though trading volume was significantly lower than average. Despite the stock trading below its average analyst target price of $7.47, analysts generally maintain a "Moderate Buy" rating. The company continues to report losses, with a negative EPS of $0.24 and revenue of $1.15 million in the last quarter, while institutional investors hold 70.37% of its shares.
Prime Medicine (NASDAQ:PRME) Trading Down 6.9% - Should You Sell?
Prime Medicine (NASDAQ:PRME) saw its shares drop by 6.9% to approximately $3.30, with a significantly reduced trading volume compared to its average. Despite a consensus "Moderate Buy" rating and an average price target of $7.69 from analysts, the company reported a quarterly loss of $0.24 per share and revenue below estimates. Institutional investors have recently modified their holdings, with some acquiring new stakes and others increasing their positions.
Prime Medicine (NASDAQ:PRME) Rating Increased to Strong-Buy at BMO Capital Markets
BMO Capital Markets has upgraded Prime Medicine (NASDAQ:PRME) to a "strong-buy" rating, contributing to a consensus "buy" rating among analysts with a target price of $7.69. The company's shares opened at $3.54, with a market capitalization of $642 million, after reporting a quarterly loss in line with estimates but revenue below expectations. Institutional investors hold a significant 70.37% of the company's stock.
Prime Medicine Company Profile & Introduction
This document provides a company profile and introduction for Prime Medicine. It outlines the key aspects of the company's operations and its position in the market. Further details would typically include its mission, technology, and strategic goals.
PRIME MEDICINE, INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $9
BMO has initiated coverage on Prime Medicine, Inc. with an Outperform rating. The firm has set a price target of $9 for the company's stock. This report was originally published by Reuters.
BMO initiates Prime Medicine stock with outperform rating
BMO Capital has initiated coverage on Prime Medicine (NASDAQ:PRME) with an outperform rating and a $9.00 price target, representing a significant upside from its current stock price. The firm highlights Prime Editing as a differentiated gene-editing platform, with lead programs PM577 and PM647 advancing toward clinical readouts in 2027. Recent developments include a favorable arbitration outcome with Beam Therapeutics and H.C. Wainwright reiterating a Buy rating after regulatory clearance for PM577a.
BMO initiates Prime Medicine stock with outperform rating
BMO Capital has initiated coverage on Prime Medicine (NASDAQ:PRME) with an outperform rating and a $9.00 price target, representing a nearly 3x upside. The firm highlighted Prime Editing as a differentiated gene-editing platform and noted that Prime Medicine's lead programs, PM577 and PM647, are advancing toward clinical readouts in 2027. This follows a favorable arbitration outcome with Beam Therapeutics and positive reiterations from other analysts, underscoring the company's progress in its therapeutic projects despite burning cash.
Prime Medicine, Inc. Stock 12‑Month Price Target Cut to $6.92, Implies 124% Upside
The average 12-month price target for Prime Medicine, Inc. (PRME) stock has been lowered from $7.12 to $6.92 by 9 analysts, yet this new target still suggests a significant 124% potential upside from its August 14th closing price. The consensus rating for PRME remains a "Buy" among 12 analysts, with 9 recommending a Buy and 3 a Hold.
Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright
HC Wainwright has revised its Q3 2026 EPS estimate for Prime Medicine (NASDAQ: PRME) to a loss of $0.28 per share, a slight improvement from the previous forecast of $0.29. Despite maintaining a "Buy" rating and an $8.00 price target, analysts still anticipate the company will remain unprofitable until 2030. Prime Medicine recently reported a quarterly loss of $0.24 per share, meeting consensus, but its revenue of $1.15 million significantly missed analyst estimates of $4.40 million.
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright has reiterated its Buy rating for Prime Medicine (PRME.US) and maintained its target price at $8. This indicates a continued positive outlook from the firm regarding Prime Medicine's stock performance.
Renaissance Technologies LLC Sells 408,120 Shares of Prime Medicine, Inc. $PRME
Renaissance Technologies LLC has reduced its stake in Prime Medicine, Inc. (NASDAQ:PRME) by 35.5%, selling 408,120 shares but still retaining 741,039 shares valued at approximately $2.58 million. This comes as Prime Medicine reported a quarterly loss of $0.24 per share, meeting analyst estimates, yet its revenue of $1.15 million fell short of the $4.40 million forecast. Despite ongoing negative profitability, analysts maintain a "Moderate Buy" consensus with an average price target of $7.53, significantly above the current stock price of around $3.08.
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine, Inc. announced its financial results for the second quarter of 2026 and provided business updates, highlighting significant progress in its clinical programs. The company received IND and CTA clearances for PM577a in Wilson disease, securing rights for PM647 in Alpha-1 Antitrypsin Deficiency, and was granted Regenerative Medicine Advanced Therapy (RMAT) designation for PM359. Prime Medicine reported a net loss of $42.1 million for the quarter and a cash position of $108.8 million, projecting a cash runway into 2027.
Prime Medicine (NASDAQ:PRME) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Prime Medicine (NASDAQ:PRME) from a "strong sell" to a "sell" rating, while other analysts maintain a "Moderate Buy" consensus with an average price target of $7.53. The company's shares opened at $3.08, significantly below its 52-week high, and it met EPS expectations but fell short on revenue. Institutional investors hold a substantial stake in Prime Medicine, with some firms recently increasing their positions.
Prime Medicine, Inc. 2026: Revenue $11.04M, EPS ($0.24) — 10-Q Summary
Prime Medicine, Inc. (PRME) reported its Q2 2026 financial results, showing revenue of $11.04 million and a net loss of ($42.11M), resulting in a diluted EPS of ($0.24). This represents a decrease in revenue but an improvement in net loss and EPS compared to the prior-year quarter. The company attributed growth to higher product sales, increased service uptake, and a strategic shift towards digital and direct-to-consumer channels.
BRIEF-Prime Medicine, Inc. Q2 EPS USD -0.24
Prime Medicine, Inc. reported its Q2 earnings per share (EPS) at USD -0.24. This brief update was sourced from Reuters and made available on TradingView.
Prime Medicine expects 2027 data from two liver gene therapies
Prime Medicine reported its second-quarter 2026 financial results, including a narrowed net loss of $42.1 million and cash reserves of $108.8 million, expected to fund operations into 2027. The company announced significant pipeline progress, with initial clinical data for its two liver gene therapies, PM577a (Wilson disease) and PM647 (Alpha-1 Antitrypsin Deficiency), anticipated in 2027. Additionally, PM359 received an FDA RMAT designation, supporting an expedited path toward a potential BLA submission in the first half of 2027.
Prime Medicine (NASDAQ:PRME) Announces Earnings Results, Meets Estimates
Prime Medicine (NASDAQ:PRME) announced its earnings results, reporting a quarterly loss of $0.24 per share, which matched analysts' consensus estimates. Despite this, the company continues to face deeply negative profitability metrics, including a net margin of -4,917.55%. Shares traded down to $2.95, near its 52-week low, while institutional investors hold a significant portion of its stock, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $7.53.
Prime Medicine, Inc. (PRME) stock price, news, quote and history
This Yahoo Finance page provides comprehensive information on Prime Medicine, Inc. (PRME), including its current stock price, trading activity, historical data, and company overview. It highlights key financial metrics, recent news, performance comparisons against the S&P 500, and analyst ratings, alongside details of its therapeutic product pipeline and Prime Editing technology. The article also lists comparable biotechnology companies and general market data.
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) reported a Q2 loss of $0.24 per share, aligning with Zacks Consensus Estimate but missing revenue estimates significantly at $1.15 million. The company has consistently missed revenue expectations over the last four quarters, and its shares have underperformed the S&P 500 year-to-date. Despite the Q2 results, the stock currently holds a Zacks Rank #2 (Buy) due to favorable estimate revisions ahead of the report.
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine has reported its second-quarter 2026 financial results, highlighting significant progress in its clinical programs. The company received IND and CTA clearances for PM577a in Wilson disease, securing a global Phase 1/2 program, and an arbitration resolution affirmed its rights to PM647 for Alpha-1 Antitrypsin Deficiency, with regulatory submission expected in Q3 2026. PM359 for chronic granulomatous disease also received Regenerative Medicine Advanced Therapy designation, moving towards a BLA submission in H1 2027, all while maintaining a cash runway into 2027.
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine has announced its second-quarter 2026 financial results, highlighting significant progress in its clinical programs. The company received IND and CTA clearances for PM577a in Wilson disease, securing a global Phase 1/2 program, and anticipates initial clinical data in 2027. Additionally, Prime Medicine resolved an arbitration with Beam Therapeutics, affirming its rights to PM647 for Alpha-1 Antitrypsin Deficiency, with regulatory submission expected in Q3 2026, and PM359 received Regenerative Medicine Advanced Therapy designation, moving towards a BLA submission in the first half of 2027.
PRME|Prime Medicine Inc|Price:2.935|Chg%:+0.125
This article provides a comprehensive stock analysis of Prime Medicine Inc (PRME) from TradingKey, highlighting its "fairly valued" status within the Biotechnology & Medical Research industry. The company, which specializes in gene editing therapies, has significant growth potential, high institutional ownership, and a strong "Buy" rating from analysts with a target price of $7.12. Despite recent weak stock market performance, its fundamentals are stable, and the stock is trading sideways, making it suitable for range-bound swing trading.
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages
Prime Medicine, Inc. (NASDAQ:PRME) has received an average "Moderate Buy" recommendation from eight brokerages, with six analysts rating it a buy, one a strong buy, and one a sell. The average 12-month price target is $7.53, significantly higher than its recent share price of $2.92. Despite missing quarterly earnings estimates with a loss of $0.28 per share on $0.86 million in revenue, institutional investors like State Street Corp and Balyasny Asset Management have recently increased their stakes in the company.
Prime Medicine(PRME) Stock Options Chain | Quotes & News
This article provides access to the stock options chain for Prime Medicine (PRME), including detailed quotes and relevant news. It serves as a resource for investors interested in the company's options trading data and market developments.
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Prime Medicine, Inc. (PRME) is expected to report a year-over-year increase in earnings and higher revenues for Q2 2026. However, Zacks' Earnings ESP model, which compares the Most Accurate Estimate to the Zacks Consensus Estimate, suggests that analysts have recently become bearish, resulting in an Earnings ESP of -15.86%. Despite a Zacks Rank #2 (Buy), this combination makes it difficult to conclusively predict an earnings beat, especially given the company has only surpassed EPS estimates once in the last four quarters.
Redmile Group LLC Takes $5.54 Million Position in Prime Medicine, Inc. $PRME
Redmile Group LLC has acquired a new position in Prime Medicine, Inc. (NASDAQ:PRME) worth approximately $5.54 million, making it their 28th largest holding. Other institutional investors have also adjusted their stakes in the gene editing company. Analysts currently have an average "Moderate Buy" rating for Prime Medicine with an average target price of $7.53, despite the company reporting a wider-than-expected loss in its last earnings call.
ADAR1 Capital Management LLC Makes New Investment in Prime Medicine, Inc. $PRME
ADAR1 Capital Management LLC has initiated a new position in Prime Medicine, Inc. (NASDAQ:PRME) by purchasing 1,973,282 shares valued at approximately $6.87 million during the first quarter. This investment makes ADAR1 Capital Management LLC the owner of about 1.09% of Prime Medicine. Several other institutional investors have also adjusted their holdings in the company, which currently holds a "Moderate Buy" rating from analysts with a consensus target price of $7.53.
Prime Medicine Inc (PRME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Prime Medicine Inc (PRME), noting that relevant data for business segments and profit contribution have not yet been disclosed by the company for FY2025 and FY2024. It highlights that the company reported $4.63 million in revenue from the United States, representing 0.00% of the total, indicating a lack of comprehensive disclosure for a full revenue picture.
Prime Medicine Market Sentiment
This article provides an overview of market sentiment for Prime Medicine (PRME), detailing analyst consensus, short interest, options flow, and recent analyst actions. Key signals show a "Buy" analyst consensus, 24.6% short float, and a 1.58 P/C ratio for options. The article also lists historical analyst ratings, price target changes, and actions from various firms for PRME.
Price to earnings forward of Prime Medicine, Inc. – NASDAQ:PRME
This article provides financial information for Prime Medicine, Inc. (NASDAQ: PRME), specifically focusing on its forward price-to-earnings ratio. The content appears to be a financial data page from TradingView, indicating the company's stock market status and offering various analytical tools and data points.
